the problem is unless a biotech introduces penalty clauses in a contract with Cro or maintains strong oversight of what the Cro is doing, like is on at them almost daily, there is little incentive for a Cro to do anything quickly. They’ll be happy to keep getting the monthly cheque as long as the study keeps going.
Ann: Quarterly Activities/Appendix 4C Cash Flow Report, page-118
-
- There are more pages in this discussion • 42 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add BIT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
1.8¢ |
Change
0.000(0.00%) |
Mkt cap ! $16.24M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 2145000 | 1.7¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 1.8¢ | 63551 | 2 |
View Market Depth
| Last trade - 09.00am 13/09/2024 (20 minute delay) ? |
| BIT (ASX) Chart |
Day chart unavailable